Immunological considerations for COVID-19 vaccine strategies
Top Cited Papers
- 4 September 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 20 (10), 615-632
- https://doi.org/10.1038/s41577-020-00434-6
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years.Keywords
This publication has 193 references indexed in Scilit:
- Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine CandidatemBio, 2013
- Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple SpeciesScience Translational Medicine, 2012
- A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon ChallengeJournal of Virology, 2011
- Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyThe Lancet Infectious Diseases, 2011
- T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected MiceJournal of Virology, 2010
- Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory diseaseVirology, 2010
- Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunityVirology, 2009
- Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoVVaccine, 2008
- Immune responses against severe acute respiratory syndrome coronavirus induced by virus‐like particles in miceImmunology, 2007
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990